Michael Petusky: All right. Great stuff. Thank you.
Operator: Please standby for the next question. The next question comes from David Turkaly with Citizens JMP. Your line is open.
David Turkaly: Hey, good morning and congrats on getting to the halfway point of your LRP. Chris, I think you said in your commentary just answering a question venous and arterial closure. Can you tell us today like how that breaks out? What does your mix look like right now with VASCADE in those two areas?
Christopher Simon: Yes. So for VASCADE, it’s roughly an 80-20 split, where 80% electrophysiology, really looking at AFib ablation closure. And that’s the MVP product, 80% of the portfolio and growing nicely. And we’ll add XL on top of that, that will some cannibalization, but for sure further accelerate the growth. The base VASCADE product is predominantly PCI in interventional cardiology setting. And one of the things we surprised ourselves positively on, Dave, as we kind of ran this implementation is both the VASCADE product and MVP grew proportionately as we doubled and then doubled again our commercial footprint. It’s still an 80-20 split, but we are clearly moving things forward in PCI, because we’ve got a much more pronounced clinical presence.
Now dropping in OpSens guidewires, which are predominantly focused in interventional as well, we’ll just have that much more share of voice, share of mind. We’re in on the procedures already. So we’re hoping it’s going to be highly synergistic. For sure, VASCADE an 80-20 split. When we talk about guidewires, Opto is the larger of the two products, but we think SavvyWire has the MVP XL type of growth potential. So stay tuned for more on that. But that really builds our presence, the same way that Enzo builds our presence in ablation. So we’re starting to get pretty excited about the broader based opportunities for interventional, but it really is a tale of two closely adjacent, but distinct call points between electrophysiology and interventional cardiology.
David Turkaly: Thank you for that. James, congrats on two years. I guess, and all the detail on new credit facility. I was wondering if you might be able to frame out what interest expense is going to look like in fiscal ’25 or at least maybe hit us with the average rate or what you anticipate you’ll have out in the year?
James D’Arecca: Yes. Thanks, Dave. Interest expense will be about a $0.16 headwind for us in fiscal year 2025 as compared to what we had in ’24. That will be highly dependent that assumes that the debt structure that we have right now continues through the year. So we’re certainly keeping our fingers crossed for a few rate cuts.
David Turkaly: Great. Thanks a lot.
Operator: This concludes our question-and-answer session. Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.
